Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed epithelial ovarian, primary peritoneal, and/or fallopian tube cancer that is platinum-resistant or refractory
At least one measurable and/or non-measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (V) 1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Left ventricular ejection fraction (LVEF) greater than or equal to (\>/=) 50 percent (%)
Negative serum pregnancy test in women of childbearing potential
Women of childbearing potential must agree to use effective contraception as defined by protocol during and for at least 6 months post study treatment
You may not be if
Non-epithelial tumors
Ovarian tumors with low malignant potential (borderline tumors)
History of other malignancy of prognostic relevance within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma, or tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the breast
Previous treatment with more than 2 chemotherapy regimens
Any prior radiotherapy to the pelvis or abdomen
History or evidence on physical/neurological examination of central nervous system disease unrelated to cancer (uncontrolled seizures), unless adequately treated with standard medical therapy
Pre-existing peripheral neuropathy \>/= common toxicity criteria (CTC) grade 2 (applicable for paclitaxel cohort only)
Inadequate organ function
Uncontrolled hypertension or clinically significant cardiovascular disease
Current known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV)
Current chronic daily treatment with corticosteroids (\>/= 10 mg per day of methylprednisolone or equivalent), excluding inhaled steroids
History of receiving any investigational treatment within 28 days prior to first study drug administration
For Part 2 of the trial: prior enrollment into Part 1 of the trial
Concurrent participation in any therapeutic clinical trial
Clareo Health | Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
